mTOR is a downstream target of the AKT signaling pathway and an in vitro study has shown that the delivery of exosomal miR-210 could activate the mTOR signaling pathway in pancreas cancer to promote cancer cell proliferation, stemness, and gemcitabine resistance [105]. The gene discussed is AKT1; the disease is cancer.